---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-023023"
form_type: "8-K"
ticker: null
cik: "0001671818"
company_name: "Oncorus, Inc."
filed_at: "2023-05-18T23:59:59+00:00"
generated_at: "2026-06-14T21:18:32.222202+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncorus repays $20M loan with K2 HealthVentures, terminates Loan Agreement; appoints interim CFO

## Summary
- Repaid $20M principal plus ~$1.6M accrued interest and fees on May 12, 2023; Loan Agreement terminated.
- Alexander Nolte appointed as principal financial officer and accounting officer, serving as interim CFO at $400/hour.
- Mr. Nolte previously VP, Chief Accounting Officer at Syndax Pharmaceuticals; no family relationships disclosed.

## SEC filing metadata
- accession: 0000950170-23-023023
- form_type: 8-K
- cik: 0001671818
- company_name: Oncorus, Inc.
- filed_at: 2023-05-18T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02, 2.04, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671818/000095017023023023/0000950170-23-023023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671818/000095017023023023/oncr-20230512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-023023
- JSON: https://secwatch.observer/filing/0000950170-23-023023.json
- Plain text: https://secwatch.observer/filing/0000950170-23-023023.txt

## Key facts
- Executive change
  Alexander Nolte was appointed as interim Chief Financial Officer at Oncorus, Inc..
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: On May 18, 2023, the Company's board of directors appointed Alexander Nolte as the Company’s principal financial officer and principal accounting officer. Mr. Nolte will serve as the Company’s interim Chief Financial Officer pursuant to a consulting arrangement described below.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671818/000095017023023023/0000950170-23-023023-index.htm
- Material Agreements
  Oncorus, Inc. terminated Loan and Security Agreement with K2 HealthVentures LLC valued at paid in full all outstanding obligations: $20.0 million principal and approximately $1.6 million acc (effective 2023-05-12).
  - Action: termination
  - Agreement: credit facility
  - Counterparty: K2 HealthVentures LLC
  - Value: paid in full all outstanding obligations: $20.0 million principal and approximately $1.6 million acc
  - Effective: 2023-05-12
  source text: On May 12, 2023, the Company paid in full all of its outstanding obligations and other fees due under the Loan Agreement, consisting of $20.0 million in principal and approximately $1.6 million of accrued interest and related fees and expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671818/000095017023023023/0000950170-23-023023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.